In this issue:
IKEMA survival results: carfilzomib–dexamethasone ± isatuximab for RRMM
BENEFIT: deeper and more durable responses to Isa-VRd vs Isa-Rd
Dual BCMA/CD19 targeting CAR T-cell therapy efficacious in treatment naïve disease
Anti-BCMA/GPRC5D CAR T-cell therapy promising for RRMM
Early treatment of high-risk SMM may provide cure in select patients
ARROW2: Comparable efficacy and safety of once- vs twice-weekly KRd
Exercise may improve the immune system in myeloma
Early intensive DRd salvage strategy feasible after induction failure
Survival in patients with CNS-MM remains poor
High financial burden of a myeloma diagnosis
Please login below to download this issue (PDF)